Reappraisal of the clinical effect of mepolizumab - Authors' reply
Lancet Respir Med
.
2017 Jun;5(6):e21.
doi: 10.1016/S2213-2600(17)30184-4.
Epub 2017 May 26.
Authors
Geoffrey L Chupp
1
,
Eric S Bradford
2
,
Frank C Albers
3
,
Daniel J Bratton
4
,
Jie Wang-Jairaj
5
,
Linda M Nelsen
6
,
Jennifer L Trevor
7
,
Antoine Magnan
8
Affiliations
1
Yale Center for Asthma and Airways Disease, Yale School of Medicine, New Haven, CT 06520-8057, USA. Electronic address:
[email protected]
.
2
Respiratory Therapeutic Area, GlaxoSmithKline (GSK), Research Triangle Park, NC, USA.
3
Respiratory Medical Franchise, GlaxoSmithKline (GSK), Research Triangle Park, NC, USA.
4
Clinical Statistics, GSK, Stockley Park, Middlesex, UK.
5
Respiratory Therapy Area, GSK, Stockley Park, Middlesex, UK.
6
Value Evidence and Outcomes, GSK, Collegeville, PA, USA.
7
Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
8
l'Institut du Thorax, Universite de Nantes, CHU de Nantes, Nantes, France.
PMID:
28664853
DOI:
10.1016/S2213-2600(17)30184-4
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized*
Eosinophils*
Humans
Substances
Antibodies, Monoclonal, Humanized
mepolizumab